ImaginAb Executes License and Supply Agreement for CD8 ImmunoPET Technology with DynamiCure Biotechnology

LOS ANGELES, Nov. 15, 2022 /PRNewswire/ -- ImaginAb Inc., a global biotechnology company focused on developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPETâ„¢) imaging agent and radiopharmaceutical therapy (RPT) products, today announced the signing of a new multi-year, non-exclusive license...

Click to view original post